IL214337A0 - Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction - Google Patents
Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunctionInfo
- Publication number
- IL214337A0 IL214337A0 IL214337A IL21433711A IL214337A0 IL 214337 A0 IL214337 A0 IL 214337A0 IL 214337 A IL214337 A IL 214337A IL 21433711 A IL21433711 A IL 21433711A IL 214337 A0 IL214337 A0 IL 214337A0
- Authority
- IL
- Israel
- Prior art keywords
- tetraoxidobenzo
- dithiazoles
- substituted
- compositions
- methods
- Prior art date
Links
- QRWQFOHBHHIZKG-UHFFFAOYSA-N 1$l^{6},3$l^{6},2-benzodithiazole 1,1,3,3-tetraoxide Chemical class C1=CC=C2S(=O)(=O)NS(=O)(=O)C2=C1 QRWQFOHBHHIZKG-UHFFFAOYSA-N 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20627109P | 2009-01-28 | 2009-01-28 | |
| PCT/US2010/022430 WO2010088406A1 (en) | 2009-01-28 | 2010-01-28 | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL214337A0 true IL214337A0 (en) | 2011-09-27 |
Family
ID=42396011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL214337A IL214337A0 (en) | 2009-01-28 | 2011-07-28 | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8658650B2 (enExample) |
| EP (1) | EP2393785A4 (enExample) |
| JP (1) | JP2012516355A (enExample) |
| AU (1) | AU2010208176A1 (enExample) |
| CA (1) | CA2751176A1 (enExample) |
| IL (1) | IL214337A0 (enExample) |
| SG (1) | SG173465A1 (enExample) |
| WO (1) | WO2010088406A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2737699A1 (en) * | 2008-09-16 | 2010-03-25 | Merck Sharp & Dohme Corp. | Phthalimide derivative metabotropic glutamate r4 ligands |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2853532B1 (en) | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| AR098100A1 (es) * | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas y los métodos relacionados |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| EP3419981A4 (en) | 2016-02-23 | 2019-09-18 | Indiana University Research & Technology Corporation | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP3668865A1 (en) | 2017-08-16 | 2020-06-24 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| KR102024361B1 (ko) * | 2017-09-26 | 2019-09-23 | 울산과학기술원 | 벤젠 디아민 유도체를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187276A (en) * | 1983-06-18 | 1993-02-16 | Troponwerke Gmbh & Co. Kg. | 2-pyrimidinyl-1-piperazine derivatives |
| DE3321969A1 (de) | 1983-06-18 | 1984-12-20 | Troponwerke GmbH & Co KG, 5000 Köln | 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| EP1646377A4 (en) | 2003-07-11 | 2009-09-09 | Merck & Co Inc | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR |
| US20050250803A1 (en) | 2003-11-26 | 2005-11-10 | Pfizer Inc | Combination of dopamine agonists and monoamine reuptake inhibitors |
| US20060004001A1 (en) | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| WO2008066887A2 (en) * | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| CA2737699A1 (en) | 2008-09-16 | 2010-03-25 | Merck Sharp & Dohme Corp. | Phthalimide derivative metabotropic glutamate r4 ligands |
| AU2010275477A1 (en) | 2009-07-23 | 2012-02-23 | Vanderbilt University | Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators |
| IN2012DN02580A (enExample) | 2009-09-04 | 2015-08-28 | Univ Vanderbilt | |
| JP2013508413A (ja) | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| BR112012010738A2 (pt) | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| AU2011215638B2 (en) | 2010-02-11 | 2016-04-28 | Vanderbilt University | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
| KR20130079429A (ko) | 2010-05-12 | 2013-07-10 | 벤더르빌트 유니버시티 | 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 |
-
2010
- 2010-01-28 US US13/146,909 patent/US8658650B2/en active Active
- 2010-01-28 JP JP2011548305A patent/JP2012516355A/ja not_active Withdrawn
- 2010-01-28 CA CA2751176A patent/CA2751176A1/en not_active Abandoned
- 2010-01-28 EP EP10736412.7A patent/EP2393785A4/en not_active Withdrawn
- 2010-01-28 SG SG2011054608A patent/SG173465A1/en unknown
- 2010-01-28 AU AU2010208176A patent/AU2010208176A1/en not_active Abandoned
- 2010-01-28 WO PCT/US2010/022430 patent/WO2010088406A1/en not_active Ceased
-
2011
- 2011-07-28 IL IL214337A patent/IL214337A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010088406A1 (en) | 2010-08-05 |
| JP2012516355A (ja) | 2012-07-19 |
| US20110319429A1 (en) | 2011-12-29 |
| CA2751176A1 (en) | 2010-08-05 |
| AU2010208176A1 (en) | 2011-09-15 |
| US8658650B2 (en) | 2014-02-25 |
| EP2393785A4 (en) | 2013-10-30 |
| SG173465A1 (en) | 2011-09-29 |
| EP2393785A1 (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL214337A0 (en) | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL219296A0 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL218426A0 (en) | Mglur4 allosteric allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL222854A0 (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL219568A0 (en) | Aryl and heteroaryl sulfones, as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL221390A0 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, composunds, and methods of treating neurological dysfunction | |
| EP2384198A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES | |
| IL221389A0 (en) | Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological-dysfunction | |
| SMT201700346T1 (it) | Composizioni antisenso e metodi per la loro preparazione e loro uso | |
| GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
| IL200766A0 (en) | Compositions and methods for the prevention and treatment of autoimmune conditions | |
| ZA201103036B (en) | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | |
| IL214208A0 (en) | Compositions and methods for inhibition of the jak pathway | |
| EP2294166A4 (en) | OIL COMPOSITIONS FOR GEARS, METHODS OF MAKING SAME, AND USE THEREOF | |
| ZA201106577B (en) | Compounds and compositions for cognition-enhancement,methods of making,and methods of treating | |
| EP2370415A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH | |
| PL2179657T3 (pl) | Kompozycje z efuzją gazu i sposób ich wytwarzania | |
| GB0812890D0 (en) | Compositions and methods of making compositions | |
| EP2285942A4 (en) | LUBRICATING OIL COMPOSITIONS AND METHOD FOR THEIR MANUFACTURE AND USE | |
| EP2379637A4 (en) | IMPROVED PROCESSES FOR MAKING STYRENE POLYMER COMPOSITIONS AND METHODS OF USE THEREOF | |
| IL196825A0 (en) | Methods, compositions and articles of manufacture for contributing to the treatment of cancers | |
| TWI454221B (en) | Composition and method for inhibiting formation of body fat | |
| HK1165407A (en) | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| GB0808730D0 (en) | Compositions and methods for the prevention and treatment of schistosomiasis | |
| ZA200907083B (en) | Method and compositions for contributing to the treatment of cancers |